Report for: Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia

Title	Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia
Published in	Cochrane database of systematic reviews, September 2012
DOI	10.1002/14651858.cd009045.pub2
Pubmed ID	22972131
Authors	Liat Vidal, Anat Gafter-Gvili, Ronit Gurion, Pia Raanani, Martin Dreyling, Ofer Shpilberg
Abstract	Indolent B cell lymphoid malignancies include follicular lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma and marginal zone lymphomas. Chronic lymphocytic leukaemia (CLL) is a lymphoid malignancy similar to small lymphocytic lymphoma (SLL) in its leukaemic phase.Indolent lymphoid malignancies including CLL are characterised by slow growth, a high initial response rate and a relapsing and progressive disease course. Advanced-stage indolent B cell lymphoid malignancies are often incurable. If symptoms or progressive disease occur, chemotherapy plus rituximab is indicated. No chemotherapy regimen has been shown to improve overall survival compared to a different regimen.Bendamustine is efficacious in the treatment of patients with indolent B cell lymphoid malignancies. A number of randomised controlled trials have examined the effect of bendamustine compared to other chemotherapy regimens in these patients. Improved disease control with no survival benefit is shown.

View on publisher site Alert me about new mentions

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Geographical breakdown

Country	Count	As %
Unknown	1	100%

Demographic breakdown

Type	Count	As %
Members of the public	1	100%

Mendeley readers

The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
United States	1	<1%
Switzerland	1	<1%
Unknown	102	98%

Demographic breakdown

Readers by professional status	Count	As %
Student > Master	14	13%
Student > Bachelor	13	13%
Other	11	11%
Researcher	11	11%
Student > Ph. D. Student	10	10%
Other	23	22%
Unknown	22	21%

Readers by discipline	Count	As %
Medicine and Dentistry	55	53%
Nursing and Health Professions	10	10%
Psychology	4	4%
Economics, Econometrics and Finance	3	3%
Pharmacology, Toxicology and Pharmaceutical Science	2	2%
Other	7	7%
Unknown	23	22%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2016.

All research outputs

#17,665,425

of 22,678,224 outputs

Outputs from Cochrane database of systematic reviews

#11,264

of 12,298 outputs

Outputs of similar age

#123,586

of 168,582 outputs

Outputs of similar age from Cochrane database of systematic reviews

#208

of 226 outputs

Altmetric has tracked 22,678,224 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.

So far Altmetric has tracked 12,298 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.3. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,582 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.

We're also able to compare this research output to 226 others from the same source and published within six weeks on either side of this one. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.

Cochrane Database of Systematic Reviews

Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia

Mentioned by

Citations

Readers on

Twitter Demographics

Geographical breakdown

Demographic breakdown

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context